European Network to Cure ALS (ENCALS)

ALS (Amyotrophic Lateral Sclerosis) is the most common motor neuron disease, also known as Lou Gehrig’s disease. It is a devastating condition associated with degeneration of upper and lower motorneurons resulting in a fatal outcome within 1-5 years, with no significantly effective treatment available to date. ALS affects approximately 1 in 10,000 people in Europe, equivalent to a total of more than 51,000 people. ALS Centres in Europe have established ENCALS as a network to collaborate in their research for a cure of ALS.

ENCALS satellite meeting Dec 6th 2016 Dublin

Programme: Understanding Disease Heterogeneity 

The maximum number of participants has now been reached. The room's seating limit is 140 maximum.  Due to fire regulations, the venue is very strict about this. If you are not registered, you will unfortunately not be able to participate in this meeting. 

Please email info@encals.eu to place your name on a reserve list and you will be informed if a place becomes available. 

If you have registered but will not attend the satellite meeting, please email info@encals.eu so that your place can be given to an ENCALS member on the reserve list. 

Twitter using hashtag #ENCALS

News

New NIHR-BRC in Sheffield, UK

Sheffield Teaching Hospitals and the University of Sheffield, in partnership, are to be designated an NIHR-Biomedical Research Centre (BRC), with the theme of ‘Translational Neuroscience for Chronic Neurological Disorders’.

Winner 2016 PG Award

The 8th PG International Medicine Prize  was awarded to Edor Kabashi, a researcher at the Institute for Brain and Spinal Pitié Salpêtrière Hospital in Paris.